Data / Form D filings / Roka BioScience, Inc.
Roka BioScience, Inc.: Form D filings
Roka BioScience, Inc., a biotechnology company in Warren, NJ, filed 6 Form D notices with the SEC between 2009 and 2016. The latest, on September 30, 2016, reports $22.5 million sold of a $22.5 million offering to 32 investors.
Find out what Roka BioScience, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 20 INDEPENDENCE BOULEVARD, Warren, NJ, 07059
- Phone
- (908) 605-4700
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1472343
The full lists. Form D filings in New Jersey: 714 rows, $35.70, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2016 | New notice | $22,500,000 | $22,500,000 | $0 | 32 | Sep 21, 2016 | sec.gov |
| Dec 5, 2013 | New notice | $16,996,657 | $16,996,657 | $0 | 5 | Nov 20, 2013 | sec.gov |
| Jun 27, 2013 | New notice | $24,999,999 | $24,999,999 | $0 | 5 | Jun 13, 2013 | sec.gov |
| Dec 28, 2011 | Amendment | Indefinite | $27,500,000 | Indefinite | 5 | Sep 10, 2009 | sec.gov |
| May 17, 2011 | Amendment | $20,000,001 | $20,000,001 | $0 | 5 | Sep 10, 2009 | sec.gov |
| Sep 23, 2009 | New notice | $49,329,524 | $29,438,587 | $19,890,937 | 6 | Sep 10, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Lars Boesgaard | Executive Officer | |
| David G. McGirr | Director | |
| Nicholas G. Valeriani | Director | |
| Jim G. Barret, PhD | Director | |
| Michael P. Doyle | Director | |
| Fred G. Cohen | Director | |
| Jonathan G. Silverstein | Director | |
| Paul G. Thomas | Executive Officer, Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
Every Form D from the week of Sep 26, 2016 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Roka BioScience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.